Evidence & Efficacy: Lipid-Modifying Therapy

NEW second edition available

Commended in the Cardiology Category of the British Medical Association (BMA) Medical Book of the Year 2009 Awards


  • Paperback: 128 pages
  • Published: 25 Feb 2008
  • Languages: English, Greek, Turkish
  • ISBN: 9781905982035
  • Product dimensions: 148 x 210 mm (6.5 x 8.25 inches)

Book description
Hyperlipidaemia is an important risk factor for the pathogenesis of atherosclerotic vascular diseases, especially CHD. In addition to lifestyle changes, several drugs have been investigated in controlled clinical trials for their ability to correct dyslipidaemia and reduce CV morbidity and mortality. Notably, statins, which inhibit HMG CoA reductase and hence cholesterol synthesis, are very effective in reducing plasma levels of LDL cholesterol and help to reduce CV event rates. Since the early 1990s, this class of drugs has proved to be very successful in both primary and secondary prevention trials, encompassing >500,000 patient years of follow-up.

Evidence & Efficacy: Lipid-Modifying Therapy aims to provide a convenient collection of the most important controlled clinical trials in the treatment of dyslipidaemia and prevention of CV disease.

A von Eckardstein

Evidence & Efficacy: Lipid-Modifying Therapy (cover image)

Table of contents [PDF]

Sample section [PDF]

Download sales sheet [PDF]

Order this title


Trial categories

1. Major primary prevention trials with statins
West Of Scotland Coronary Prevention Study (WOSCOPS)
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial—Lipid-Lowering Trial (ALLHAT—LLT)
PROspective Study of Pravastatin in the Elderly at Risk (PROSPER)
Primary prevention of CV disease with pravastatin in Japan (MEGA)
Primary prevention of CV disease with statin therapy: a meta-analysis of randomized controlled trials

2. Major secondary prevention trials with statins
Scandinavian Simvastatin Survival Study (4S)
Cholesterol and Recurrent Events (CARE)
Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID)
Heart Protection Study (HPS)

3. Early statin treatment in ACS patients
Myocardial Ischaemia Reduction with Aggressive Cholesterol Lowering (MIRACL)
Effects of early treatment with statins on short-term clinical outcomes in ACS: a meta-analysis of randomized controlled trials
Atorvastatin for Reduction of MYocardial Damage during Angioplasty (ARMYDA)–ACS

4. CHD prevention trials with statins in patients with diabetes or the metabolic syndrome
HPS diabetes subgroup analysis
LIPID post-hoc subgroup analysis
Collaborative AtoRvastatin Diabetes Study (CARDS)
Anglo-Scandinavian Cardiac Outcomes Trial—Lipid-Lowering Arm (ASCOT—LLA) post-hoc diabetes subgroup analysis
Treating to New Targets (TNT) diabetes subgroup analysis
TNT post-hoc metabolic syndrome subgroup analysis
Atorvastatin Study for Prevention of coronary heart disease Endpoints in Non-insulin-dependent diabetes mellitus (ASPEN)

5. CHD prevention in chronic kidney disease
Die Deutsche Diabetes Dialyse (4D) Studie
4S post-hoc mild chronic renal insufficiency subgroup analysis
Statins and CV RR in patients with chronic kidney disease and end-stage renal failure

6. Stroke prevention
Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL)
Impact of statins on risk of stroke

7. Comparative hypolipidaemic efficacy, IVUS, IMT and end-point trials
Comparative dose efficacy study of atorvastatin vs simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolaemia (CURVES)
Atorvastatin versus Simvastatin on Atherosclerosis Progression (ASAP)
Statin Therapies for Elevated Lipid Levels compared Across dose ranges to Rosuvastatin (STELLAR)
Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I)
Reversal of atherosclerosis with aggressive lipid lowering therapy (REVERSAL)
PRavastatin Or atorVastatin Evaluation and Infection Therapy—Thrombolysis In Myocardial Infarction 22 (PROVE-IT TIMI 22)
VYtorin Versus Atorvastatin (VYVA)
Ezetimibe Add-on to Statin for Effectiveness (EASE)
Incremental Decrease in End points through Aggressive Lipid lowering (IDEAL)
VYTAL study
A Study To Evaluate the effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden (ASTEROID)
Meta-analysis of CV outcomes trials comparing intensive vs moderate statin therapy
Measuring Effects on intima–media Thickness: an Evaluation Of Rosuvastatin (METEOR)

8. Meta-analyses for efficacy, safety and cost–benefit calculations
Cholesterol Treatment Trialists (CTT)
Aspirin, statins or both drugs for the primary prevention of CHD events in men: a cost–utility analysis

9. Primary prevention trials with CHD end points using drugs that modify triglyceride-rich lipoproteins and/or HDL
World Health Organization (WHO) clofibrate study
Helsinki Heart Study (HHS)
Japan Eicosapentaenoic acid Lipid Intervention Study (JELIS)

10. Secondary prevention trials with CHD end points using drugs that modify triglyceride-rich lipoproteins and/or HDL
Coronary Drug Project
Veterans Affairs HDL Intervention Trial (VA-HIT)
Bezafibrate Infarction Prevention (BIP)
HDL Atherosclerosis Treatment Study (HATS)
Fenofibrate Intervention and Event Lowering in Diabetes (FIELD)